Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs01:22

MicroRNAs

23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and Spectrum of Chromosomal Abnormalities in 1366 Infertile Tunisian Men: A retrospective observational study.

La Tunisie medicale·2026
Same author

α-ketoglutarate/succinate ratio imbalance impairs thymine DNA glycosylase function and base excision repair process increasing susceptibility to pancreatic cancer.

Cell death & disease·2026
Same author

Two breasts, one breath: continuous positive airway pressure for innovative heart sparing in synchronous bilateral breast cancer radiotherapy.

Breast cancer (Tokyo, Japan)·2025
Same author

HPV testing in cervical cancer formalin-fixed paraffin embedded tissues: Reliability of the Xpert HPV test and high-risk HPV genotypes distribution in Tunisia.

PloS one·2025
Same author

Estrogen rescues muscle regeneration impaired by DUX4 in a humanized xenograft mouse model.

Cell death & disease·2025
Same author

Deciphering the efficiency of preoperative systemic-immune inflammation related markers in predicting oncological outcomes of upper tract urothelial carcinoma patients after radical nephroureterectomy.

Investigative and clinical urology·2025

Related Experiment Video

Updated: Jan 18, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.2K

Dysregulated MicroRNAs in Urinary Non-Muscle-Invasive Bladder Cancer: From Molecular Characterization to Clinical

Nouha Setti Boubaker1,2,3, Aymone Gurtner1,4, Sami Boussetta5

  • 1UOSD SAFU Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.

Cancers
|September 13, 2025
PubMed
Summary

New molecular biomarkers, including specific microRNAs (miRNAs), show promise for predicting outcomes in non-muscle-invasive bladder cancer (NMIBC). These findings could lead to improved risk stratification and personalized treatment strategies for bladder cancer patients.

Keywords:
biomarkerbladder cancerdrug interactionmicroRNApathway enrichmentprognosis

More Related Videos

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method

Published on: October 7, 2025

352
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.2K

Related Experiment Videos

Last Updated: Jan 18, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

16.2K
MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method

Published on: October 7, 2025

352
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Predicting outcomes in non-muscle-invasive bladder cancer (NMIBC), especially high-grade (HG) types, is challenging due to unpredictable recurrence and progression.
  • Existing clinical and pathological tools have limitations in accurately stratifying NMIBC patient risk.
  • There is a critical need for novel molecular biomarkers to enhance risk assessment and guide treatment decisions for NMIBC.

Purpose of the Study:

  • To evaluate the prognostic potential of eight specific microRNAs (miRNAs) in patients with primary bladder cancer.
  • To identify miRNA combinations that can accurately predict recurrence, progression, and overall survival in NMIBC.
  • To explore the functional pathways and potential therapeutic targets regulated by these miRNAs.

Main Methods:

  • Assessed prognostic value of eight miRNAs (miR-9, miR-143, miR-182, miR-205, miR-27a, miR-369, let-7c, let-7g) in 90 primary bladder cancer patients.
  • Utilized Kaplan-Meier and Cox regression analyses to correlate miRNA expression with overall survival (OS) and metastasis-free survival (MFS).
  • Employed Principal Component Analysis (PCA) for miRNA combination identification, pathway enrichment analysis (DAVID), and drug-gene interaction mapping (DGIdb) in silico.

Main Results:

  • High expression of let-7g and miR-9 correlated with better OS in high-grade NMIBC and muscle-invasive bladder cancer (MIBC), respectively.
  • MiR-9 downregulation was associated with metastasis in MIBC; miR-205 and miR-27a combinations effectively predicted intermediate-risk NMIBC progression and recurrence.
  • In silico analysis identified that these miRNAs regulate key cancer pathways (MAPK, mTOR, p53) and revealed drug-gene interactions with FDA-approved bladder cancer therapies.

Conclusions:

  • Let-7g, miR-9, miR-143, miR-182, and miR-205 show significant potential as biomarkers for predicting NMIBC outcomes.
  • Integrating these miRNAs into liquid biopsy platforms could enable non-invasive monitoring and personalized treatment strategies.
  • Further validation in larger prospective studies and functional assays is warranted to confirm these promising findings.